Drug made famous by Shkreli’s 5,000% price hike is still $750 a pill image

Ars Technica, May 4, 2018
Beth Mole, quoting W. Nicholson Price II (Academic Fellow Alumnus)


Read the full article

From the article:

Disgraced ex-pharmaceutical executive and hedge fund manager Martin Shkreli is now behind bars, facing a seven-year prison sentence for securities fraud. Yet the drug-price hike that initially thrust him into the public spotlight—and infamy—hasn’t budged, according to a sobering report by Kaiser Health News.

The outlet points out that the retail price for Daraprim (pyrimethamine) is still $750 a pill, up more than 5,000 percent from its previous price of $13.50 per pill. Worse yet, it’s not the only such case. In 2015 alone, more than 300 generic drugs saw prices increase by more than 100 percent.

Drug prices are “easy to raise and harder to lower, particularly if there’s no competition,” Nicholson Price of University of Michigan Law School told KHN.


Read more here!

health care finance health law policy pharmaceuticals regulation